Profile
David A.
Eiznhamer worked as an Assistant Director-Pharmacology & ADME at deCODE genetics, Inc. from 2002 to 2003.
He also worked as a Manager-Regulatory Affairs at MediChem Life Sciences, Inc. from 1999 to 2002.
Prior to that, he was an Executive Vice President-Clinical Development at Advanced Life Sciences Holdings, Inc. Dr. Eiznhamer holds a doctorate degree from Loyola University of Chicago.
Former positions of David A. Eiznhamer
Companies | Position | End |
---|---|---|
deCODE genetics, Inc.
deCODE genetics, Inc. Pharmaceuticals: GenericHealth Technology deCODE genetics, Inc. is a bio-pharmaceutical company. It developing and marketing products to improve the treatment, diagnosis and prevention of common diseases. deCODE applies its capabilities in chemistry and structural biology to the development of drugs in major therapeutic areas, and applies its discoveries in human genetics to bring to market DNA-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. The company was founded by Kari Stefansson and Jeffrey Gulcher in August 1996 and is headquartered in Reykjavík, Iceland. | Corporate Officer/Principal | 2003-04-30 |
MediChem Life Sciences, Inc.
MediChem Life Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Part of DGI Resolution, Inc., MediChem Life Sciences, Inc. provides research and drug discovery services. The company is based in Woodridge, IL. The company was founded in 1987 by Michael T. Flavin. MediChem Life Sciences was acquired by deCODE genetics, Inc. on March 18, 2002 for $52.85 million. | General Counsel | 2001-12-31 |
ADVANCED LIFE SCIENCES HOLDINGS, INC. | Chief Tech/Sci/R&D Officer | - |
Training of David A. Eiznhamer
Loyola University of Chicago | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 3 |
---|---|
Advanced Life Sciences Holdings, Inc.
Advanced Life Sciences Holdings, Inc. BiotechnologyHealth Technology Advanced Life Sciences Holdings, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of novel drugs in therapeutic areas of infection, cancer and inflammation. Its product candidate, Restanza, is a novel once-a-day oral antibiotic in late-stage development for the treatment of life-threatening infections including community-aquired bacterial pneumonia and biodefense pathogens including anthrax, plague and tularemia. The company was founded by Michael T. Flavin on January 1, 1999 and is headquartered in Woodridge, IL. | Health Technology |
deCODE genetics, Inc.
deCODE genetics, Inc. Pharmaceuticals: GenericHealth Technology deCODE genetics, Inc. is a bio-pharmaceutical company. It developing and marketing products to improve the treatment, diagnosis and prevention of common diseases. deCODE applies its capabilities in chemistry and structural biology to the development of drugs in major therapeutic areas, and applies its discoveries in human genetics to bring to market DNA-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. The company was founded by Kari Stefansson and Jeffrey Gulcher in August 1996 and is headquartered in Reykjavík, Iceland. | Health Technology |
MediChem Life Sciences, Inc.
MediChem Life Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Part of DGI Resolution, Inc., MediChem Life Sciences, Inc. provides research and drug discovery services. The company is based in Woodridge, IL. The company was founded in 1987 by Michael T. Flavin. MediChem Life Sciences was acquired by deCODE genetics, Inc. on March 18, 2002 for $52.85 million. | Commercial Services |
- Stock Market
- Insiders
- David A. Eiznhamer